Sociedad Americana de Hirudoterapia

Warfarin vs doac: Comparative outcomes of mechanical thrombectomy for acute ischemic stroke in atrial fibrillation patients.

Research article published in Clinical neurology and neurosurgery (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosDesarrollo de fármacosRamazanoglu et al. · Clinical neurology and neurosurgery, 2023

Abstract

PURPOSE: To compare outcomes of mechanical thrombectomy (MT) for acute ischemic stroke (AIS) in patients with atrial fibrillation (AF) taking warfarin or direct oral anticoagulants (DOACs). METHODS: A total of 71 consecutive patients with AF who underwent MT due to AIS between January 2018 and December 2021 were retrospectively analyzed. Patients were grouped as warfarin versus DOAC group. CHA2DS2-VASc, HAS-BLED, The National Institutes of Health Stroke Scale (NIHSS) at the time of admission and at 24 h, successful recanalization, post- MT complications and technical properties of MT were evaluated. Patients were divided into a good prognosis group, and a mortality group according to the 90th day mRS. RESULTS: HAS-BLED score was significantly higher in DOAC group (p = 0.006) There were no significant differences in stroke severity, successful recanalization rates, post-procedural complications and mRS 90th day scores between patients with warfarin and DOACs. CHA2DS2-VASc, NIHSS at admission and NIHSS on the 24th hour scores were significantly lower in the good mRS group (p = 0.012, p = 0.002, p < 0.001, respectively). CONCLUSION: MT is safe and effective in patients receiving warfarin or DOACs. HASBLED and CHA2DS2-VASc scores can help to predict functional outcome after MT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansWarfarinAtrial FibrillationAnticoagulantsIschemic StrokeRetrospective StudiesStrokeThrombectomyAdministration, Oral

Resumen

To compare outcomes of mechanical thrombectomy (MT) for acute ischemic stroke (AIS) in patients with atrial fibrillation (AF) taking warfarin or direct oral anticoagulants (DOACs). A total of 71 consecutive patients with AF who underwent MT due to AIS between January 2018 and December 2021 were retrospectively analyzed. Patients were grouped as warfarin versus DOAC group.

Por qué esto importa para la hirudoterapia

Contributes to the clinical and translational evidence base on thrombosis, hemostasis, and anticoagulation relevant to hirudotherapy.

Citación

Warfarin vs doac: Comparative outcomes of mechanical thrombectomy for acute ischemic stroke in atrial fibrillation patients.

Ramazanoglu et al. · Clinical neurology and neurosurgery, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.